Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Research » Update on NABNEC Study

Update on NABNEC Study

  • April 18, 2016
Update from Principal Investigator – Dr Mustafa Khasraw 
 

Neuroendocrine carcinomas (NEC) are rare cancers posing unique challenges to treatment and disease control. They commonly arise in the gastrointestinal tract (stomach, pancreas, small and large bowel).
Most patients with this disease have very poor outcome. Unfortunately, there are no prospective, randomised studies for NECs of the gastrointestinal tract.
In order to achieve a better understanding of this disease and achieve better outcomes,  the NABNEC project team, drafted a study protocol and obtained regulatory documentation and Human Research and Ethics Committee approvals to conduct the pilot NABNEC study; A feasibility study of Nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal Neuroendocrine carcinomas.
The contributions of the Unicorn Foundation and Rob MacGregor research fund supported the pilot study including establishing protocol, patient consent forms, data system and ethics approval for study that was granted in September 2014.
The study recruited its first patient in July 2015 and a total of 6 trial sites in Victoria, NSW, South Australia and Tasmania have successfully been opened and are actively identifying and screening patients.
Supported by the successful clinical implementation of the pilot study, a large grant was secured from the National Health Medical Research Council (NHMRC) to expand the project to a two-arm randomised control trial. Pleasingly, ethics approval of this project expansion was approved in April 2016 and the randomised study will open at 20 study sites across Australia and New Zealand.
None of this would have been possible without the help of the Rob MacGregor research grant.

Share this post

Recent posts

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

June 16, 2025

2025 Impact Report

June 16, 2025

Be the Voice for NET Patients in WA – Join Our CAG Team

June 10, 2025

BioPharmaDispatch 2025: Putting NETs on the National Agenda

May 27, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousDiet and Nutrition Webinar 2 – Save the Date 30th May 2016
NextDefining NETs – Research project now recruitingNext

Related Posts

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

NeuroEndocrine Cancer Australia (NECA) was proud to attend the 5th Neuroendocrine Tumour (NET) Preceptorship held 13 & 14th June at Peter MacCallum Cancer Centre in

NECA at ENETS 2025: Advancing NET Care on the Global Stage

NeuroEndocrine Cancer Australia at ENETS 2025: Advancing NET Care on the Global Stage NeuroEndocrine Cancer Australia (NECA) proudly represented Australia at the 22nd Annual European

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin